Von Willebrand factor and angiopoietin-2: Toward an acute lung injury endothelial endophenotype?

Critical Care Medicine

Volumn 40, Issue 6, 2012, Pages 1966-1967

  Meyer, Nuala J ^a   Christie, Jason D ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

acute lung injury; angiopoietin 2; critical illness; outcomes; vWF

Indexed keywords

ANGIOPOIETIN 2; VON WILLEBRAND FACTOR;

ACUTE LUNG INJURY; EDITORIAL; HUMAN; LUNG ENDOTHELIUM; MORTALITY; PRIORITY JOURNAL;

ACUTE LUNG INJURY; ANGIOPOIETIN-2; FEMALE; FLUID THERAPY; HUMANS; MALE;

EID: 84861501693     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31824c8fad     Document Type: Editorial

References (19)

1. Rice TW, Wheeler AP, Thompson BT, et al; NHLBI ARDS Clinical Trials Network: Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 2011; 306:1574-1581
2. Kumar A, Zarychanski R, Pinto R, et al; Canadian Critical Care Trials Group H1N1 Collaborative: Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:1872-1879
3. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al: Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880-1887
4. Estenssoro E, Ríos FG, Apezteguía C, et al; Registry of the Argentinian Society of Intensive Care SATI: Pandemic 2009 influenza A in Argentina: A study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med 2010; 182:41-48
5. Matthay MA, Brower RG, Carson S, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Randomized, placebo-controlled clinical trial of an aerosolized ß2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011; 184:561-568
6. Calfee CS, Gallagher D, Abbott J, et al; the NHLBI ARDS Network: Plasma angiopoietin-2 in clinical acute lung injury: Prognostic and pathogenetic significance. Crit Care Med 2012; 40:1731-1737
7. Wiedemann HP, Wheeler AP, Bernard GR, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575
8. Wheeler AP, Bernard GR, Thompson BT, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213-2224
9. van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, et al: Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008; 63:903-909
10. Ong T, McClintock DE, Kallet RH, et al: Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients. Crit Care Med 2010; 38:1845-1851
11. Gallagher DC, Parikh SM, Balonov K, et al: Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008; 29:656-661
12. Meyer NJ, Li M, Feng R, et al: ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio. Am J Respir Crit Care Med 2011; 183:1344-1353
13. Su L, Zhai R, Sheu CC, et al: Genetic variants in the angiopoietin-2 gene are associated with increased risk of ARDS. Intensive Care Med 2009; 35:1024-1030
14. Eklund L, Olsen BR: Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 2006; 312:630-641
15. Lee WL, Slutsky AS: Sepsis and endothelial permeability. N Engl J Med 2010; 363:689-691
16. Kümpers P, Gueler F, David S, et al: The synthetic Tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care 2011; 15:R261
17. David S, Park JK, Meurs M, et al: Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine 2011; 55:251-259
18. David S, Ghosh CC, Kümpers P, et al: Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. Am J Physiol Lung Cell Mol Physiol 2011; 300:L851-L862
19. Ware LB, Eisner MD, Thompson BT, et al: Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 2004; 170:766-772